Bristol And Ambrx To Collaborate On Preclinical Assets For Type 2 Diabetes, Heart Failure

Bristol's second "String of Pearls" transaction in as many days includes a $24 million upfront payment to privately held Ambrx.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet